Verizon's dividend yield and Merck’s growth lead the Dow Dogs. Read why they’re set for solid returns, with other top picks ...

Highlights,Citigroup revised its price target for Merck & Co., adjusting it from $125 to $115 while maintaining an optimistic ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

Highlights,Price target adjustment,Citigroup analysts revised Merck’s target from $125.00 to $115.00.,Stock performance trends,The company’s stock has fluctuated within a defined price range over the ...

Merck’s Gardasil sales fell short of expectations in the fourth quarter, and the company pulled its long-term target of $11 ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street's estimates, boosted in part by the performance of top asset Keytruda. The drug company logged net income of $3.74 ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...

Financial giants have made a conspicuous bearish move on Merck & Co. Our analysis of options history for Merck & Co MRK revealed 12 unusual trades. Delving into the details, we found 33% of ...

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our Earnings Yield Investor model based on the published strategy ...